Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,120 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Type 1 Clear all
Completed Phase 2 Interventional Results available

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

NCT00993148
View directory record Official record
Conditions
HIV-1 Infection, HIV Infections
Interventions
maraviroc, darunavir, ritonavir
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW873140, Kaletra (lopinavir/ritonavir)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2Phase 3 Interventional

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

NCT00612898
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine, lamivudine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

NCT01499199
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 6, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus, CMV
Interventions
Letermovir Oral Tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 6, 2026, 4:12 PM EDT
Completed No phase listed Observational

IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence

NCT02140944
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
12 Months and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 6, 2026, 4:12 PM EDT
Completed No phase listed Observational

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

NCT00219934
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral therapy
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
16 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

NCT00257621
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW640385, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 4:12 PM EDT
Not listed Not applicable Interventional

Pilot Study of Raltegravir Lipodystrophy IISP

NCT01164605
View directory record Official record
Conditions
HIV Infection
Interventions
Raltegravir
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Motiv82Change: an HIV Prevention Study for Young Latino Men

NCT00877695
View directory record Official record
Conditions
HIV Infections
Interventions
Entre Culturas: Navigating Culture, Identity, and HIV Risk
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 4 Interventional

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

NCT00161434
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
valacyclovir, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Not applicable Interventional

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection

NCT00002177
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

NCT00000944
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin During Nicotine Withdrawal

NCT03593538
View directory record Official record
Conditions
Smoking, HIV-1-infection
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors

NCT00007449
View directory record Official record
Conditions
HIV Infections
Interventions
DPC 083
Drug
Lead sponsor
Dupont Applied Biosciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Bradenton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity Trial of IHV01

NCT02756208
View directory record Official record
Conditions
HIV Infection
Interventions
300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine, Placebo
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

NCT00000868
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Early Phase 1 Interventional

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

NCT03316274
View directory record Official record
Conditions
Kaposi Sarcoma, HIV/AIDS, Immunosuppression
Interventions
Nivolumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 3 Interventional

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

NCT00046176
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
52
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

A Study of Anti-HIV Monoclonal Antibody KD-247

NCT00917813
View directory record Official record
Conditions
HIV Infections
Interventions
KD-247, Physiological saline
Drug
Lead sponsor
The Chemo-Sero-Therapeutic Research Institute
Industry
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 6, 2026, 4:12 PM EDT
Completed Not applicable Interventional

The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients

NCT00002289
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:12 PM EDT